Passage Bio

PASG

Market cap $22.3M

Overview Fund Activity

7.00 USD

+0.03

0.43%

At close Updated Sep 12, 4:00 PM EDT

1 day

0.43%

5 days

-3.31%

1 month

24.78%

3 months

-18.89%

6 months

-12.5%

Year to date

-57.83%

1 year

-53.08%

5 years

-97.91%

10 years

-98.42%

About: Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Employees: 60

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

240% more call options, than puts

Call options by funds: $17K | Put options by funds: $5K

157% more capital invested

Capital invested by funds: $12.8M [Q1] → $33M (+$20.2M) [Q2]

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

0.11% less ownership

Funds ownership: 2.93% [Q1] → 2.82% (-0.11%) [Q2]

5% less funds holding

Funds holding: 41 [Q1] → 39 (-2) [Q2]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

43% upside

Avg. target

$59

746% upside

High target

$120

1,614% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity Whitney Ijem	$67	Buy Maintained	14 Aug 2025
Guggenheim Debjit Chattopadhyay	$10	Buy Maintained	14 Aug 2025
Wedbush Yun Zhong	$40	Outperform Maintained	13 Aug 2025
Chardan Capital Geulah Livshits	$120	Buy Maintained	24 Jun 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet

The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York City.

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Zacks Investment Research

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Submitted amended upliFT-D study protocol to global trial sites and health authorities Cash runway into 1Q 2027 PHILADELPHIA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights. “We continue to be encouraged by the emerging data from our upliFT-D clinical trial, which underscore the potential of PBFT02 to offer differentiated therapy for the FTD-GRN patient community.

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Announces 1-for-20 Reverse Stock Split

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 12:01 a.m. Eastern time on July 14, 2025. Passage Bio's common stock will begin trading on a post-reverse stock split basis on July 14, 2025, under the Company's existing trading symbol “PASG” with a new CUSIP number of 702712 209. The reverse stock split is intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

Passage Bio Announces 1-for-20 Reverse Stock Split

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and provided program updates and anticipated milestones. “We are pleased to share updated data highlighting the promise of PBFT02 for the frontotemporal dementia community.

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing process for PBFT02 at American Society of Gene and Cell Therapy (ASGCT) 28 th Annual Meeting Cash runway into 1Q 2027 PHILADELPHIA, May 13, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights. “We made steady progress in executing against our core operational objectives this quarter as we focus on the enrollment of FTD-GRN and FTD-C9orf72 patients in our ongoing global Phase 1/2 upliFT-D trial of PBFT02,” said Will Chou, M.D.

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Zacks Investment Research

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided recent business highlights. “We are pleased to report strong performance in 2024 as we meaningfully advanced our PBFT02 program, delivering promising data in FTD-GRN patients showing robust, durable progranulin expression and early evidence of improvement in a disease progression biomarker.

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:

Passage Bio to Participate in Upcoming Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™